samedan logo
 
 
spacer
home > ict > summer 2018 > regulatory guidance on outsourcing
PUBLICATIONS
International Clinical Trials

Regulatory Guidance on Outsourcing

The landmark guidelines for Good Clinical Practice globally were released by the ICH in 1996 – the now-famous ICH GCP E6. This was the culmination of a number of years’ work by the combined efforts of the regulatory agencies and industry associations of Europe, Japan, and the US, along with consideration of practices in Australia, Canada, the Nordic countries, and the WHO. The aim of the guideline was the harmonisation of regulatory requirements in what was then the regions of the world in which the majority of drug trials were conducted, namely Europe, the US, and Japan.

A review of the guideline reveals that a significant proportion of the document is taken up with describing the roles and responsibilities of various key players in the conduct of a drug trial. Entire sections are given over to the duties of an institutional review board (IRBs)/independent ethics committee (Section 3), an investigator (Section 4), the responsibilities of a sponsor (Section 5), and, within that, the activities associated with monitoring (5.18). The effects of this have been several-fold. The relationship between a sponsor and an investigator has been clearly established and a universal model for how ethics committees/IRBs should be set up and operate has been created. Additionally, the activities associated with monitoring have become the universal blueprint for the job description for a clinical research monitor/associate.

A lot has happened in the clinical research sector since the release of E6. The growth and widespread use of electronic data capture was one of the factors behind the release of EMA’s Reflection Paper on Risk Based Quality Management in Clinical Trials in 2013. Included in the glossary of this document is the definition of central monitoring, a concept that was not readily achievable in 1996 because of the reliance on predominantly paperbased data capture systems at the time. Also, in 2013 and in response to the advances in data capture, the FDA produced its Guidance for Industry, ‘Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring’. As with the EMA document, the subject of centralised monitoring is comprehensively covered, including a list of alternative monitoring techniques.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Martin Robinson is Co-Founder and Executive Vice President at IAOCR. He has worked across the international biopharmaceuticals industry for nearly 30 years, and his extensive experience includes setting up a number of clinical research business ventures. Using his clinical operations and workforce development expertise, Martin is a leading expert in clinical research competence, at an individual and organisational level.
spacer
Martin Robinson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

2019 Pharmapack Awards

Pharmapack Europe have announced entries for the 2019 Pharmapack Awards are now open across both the ‘Exhibitor Innovation’ and ‘Health Products’ categories with a closing date of 30th November 2018. The Health Products category will include two winners with one for Patient-Centric Design – which is launched in partnership with HCPC Europe (Healthcare Compliance Packaging Council of Europe) – and a second introduced alongside Adelphe for Eco-design in health packaging and drug delivery devices. Pharmapack Europe have also announced that they’re accepting applications for the start-up hub which provides young start-up companies servicing the pharma industry with the benefit of valuable networking and learning opportunities at half the price of a regular stand.
More info >>

White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

 
Industry Events

SMi Presents the 11th Adaptive Designs in Clinical Trials Conference 2019

1-2 April 2019, Holiday Inn Kensington Forum, London

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement